Judy Kim

Apr 5, 2024 | ophthalmologytimes.com | Judy Kim |Peter Kaiser

April 5, 2024Experts discuss the use of steroids, particularly in the context of diabetic macular edema (DME). The inflammatory nature of DME reveals the effectiveness of steroids, especially in cases where persistent fluid remains despite anti-VEGF treatment. SummaryExperts conclude their discussion reflecting on recent therapeutic advancements and novel approaches on the horizon.

Apr 5, 2024 | ophthalmologytimes.com | Judy Kim |Peter Kaiser

April 5, 2024Experts discusses concerns related to the use of new agents, focusing on intraocular inflammation (IOI) and potential batch variations in biologics faricimab and aflibercept. He emphasizes close monitoring for IOI and advises clinicians to scrutinize patients for any signs of inflammation during follow-up visits.

Apr 5, 2024 | ophthalmologytimes.com | Judy Kim |Peter Kaiser

April 5, 2024Peter Kaiser, MD shares his early experiences with faricimab and high dose aflibercept for nAMD and DME. He notes positive outcomes, especially with hard-to-treat patients, and emphasizes the ongoing evaluation of patient response to treatment. SummaryExperts share their clinical experiences using second-generation therapeutics to manage retinal diseases. In early experiences with these drugs for neovascular AMD and DME, the feedback has been generally positive.

Mar 29, 2024 | ophthalmologytimes.com | Judy Kim |Peter Kaiser

March 29, 2024Peter Kaiser, MD discusses the utilization of newer agents, faricimab and high dose aflibercept, for refractory patients who haven't responded well to previous treatments and for patients doing well but aiming to extend dosing intervals. SummaryIn the provided transcript, the physicians discuss the use of newer agents, such as faricimab and high-dose aflibercept, in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Mar 29, 2024 | ophthalmologytimes.com | Peter Kaiser |Judy Kim

SummaryExperts discuss the use of steroids in the treatment of diabetic macular edema (DME). They agree that steroids can be beneficial in DME due to its inflammatory nature, especially in patients with persistent fluid despite anti-VEGF treatment. However, they note that steroids are often added later in the treatment course in the United States compared to other countries like Italy and Japan.